What are the Current Clinical Trials and Outcomes?
Several STAT3 inhibitors are undergoing clinical trials to evaluate their efficacy and safety in cancer patients. For instance, OPB-51602 and OPB-31121 have progressed to phase I and phase II trials. Preliminary results indicate some degree of antitumor activity, although further studies are needed to fully understand their therapeutic potential and optimize dosing strategies.
